IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
33.19
+0.16 (0.48%)
At close: Mar 6, 2026, 4:00 PM EST
33.85
+0.66 (1.99%)
After-hours: Mar 6, 2026, 7:36 PM EST
IDEAYA Biosciences Revenue
In the year 2025, IDEAYA Biosciences had annual revenue of $437.42M with 3,024.43% growth. IDEAYA Biosciences had revenue of $21.75M in the quarter ending December 31, 2025, with 55.37% growth.
Revenue (ttm)
$437.42M
Revenue Growth
+3,024.43%
P/S Ratio
13.33
Revenue / Employee
$1,508,345
Employees
145
Market Cap
2.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 437.42M | 423.42M | 3,024.43% |
| Dec 31, 2024 | 14.00M | -32.77M | -70.07% |
| Dec 31, 2023 | 46.77M | -55.09M | -54.08% |
| Dec 31, 2022 | 101.86M | 45.98M | 82.28% |
| Dec 31, 2021 | 55.88M | 16.81M | 43.01% |
| Dec 31, 2020 | 39.08M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 588.99M |
| Tarsus Pharmaceuticals | 451.36M |
| Arcutis Biotherapeutics | 376.07M |
| Arcus Biosciences | 247.00M |
| Beam Therapeutics | 139.74M |
| Viridian Therapeutics | 70.85M |
| Dianthus Therapeutics | 3.08M |
IDYA News
- 8 days ago - Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - Business Wire
- 8 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 10 days ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC - PRNewsWire
- 12 days ago - IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript - Seeking Alpha
- 12 days ago - IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer - PRNewsWire
- 17 days ago - IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript - Seeking Alpha
- 18 days ago - IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events - PRNewsWire